The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2123-2131

  Gehring, Gerrit ^a   Rohrmann, Katrin ^a   Atenchong, Nkacheh ^a   Mittler, Eva ^b,d   Becker, Stephan ^b   Dahlmann, Franziska ^c   Pöhlmann, Stefan ^c   Vondran, Florian W R ^a   David, Sascha ^a   Manns, Michael P ^a   Ciesek, Sandra ^a   von Hahn, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c GERMAN PRIMATE CENTER   (Germany)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium channels; Cationic amphiphiles; Haemorrhagic fever

Indexed keywords

AMIODARONE; ARTESUNATE; CATHEPSIN B; CATHEPSIN L; CYCLOSPORIN A; DRONEDARONE; EPIGALLOCATECHIN GALLATE; ERLOTINIB; ETHOSUXIMIDE; FINGOLIMOD; GLYCOPROTEIN; IMATINIB; LIDOCAINE; METOPROLOL; RAPAMYCIN; SORAFENIB; SOTRASTAURIN; SUNITINIB; VERAPAMIL; ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL BLOCKING AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CELL STRUCTURE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; EBOLA VIRUS; FILOVIRUS; HOST CELL; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS PARTICLE; ANALOGS AND DERIVATIVES; ANIMAL; BUNYAVIRIDAE; CELL LINE; DRUG EFFECTS; EBOLAVIRUS; LASSA VIRUS; MARBURGVIRUS; NEW WORLD ARENAVIRUS; VESICULAR STOMATITIS INDIANA VIRUS;

ADRENERGIC ANTAGONISTS; AMIODARONE; ANIMALS; ARENAVIRUSES, NEW WORLD; BUNYAVIRIDAE; CALCIUM CHANNEL BLOCKERS; CELL LINE; EBOLAVIRUS; HUMANS; LASSA VIRUS; MARBURGVIRUS; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS; VERAPAMIL; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS INTERNALIZATION;

EID: 84903624061     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku091     Document Type: Article

References (59)

1. Feldmann H, Geisbert T.W. Ebola haemorrhagic fever. Lancet 2011; 377: 849-62.
2. Geisbert TW, Hensley LE, Larsen T et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163: 2347-70.
3. Geisbert TW, Young HA, Jahrling PB et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163: 2371-82.
4. Baskerville A, Fisher-Hoch SP, Neild GH et al. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 1985; 147: 199-209.
5. Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastructural Pathol 1998; 22: 3-17.
6. Ito H, Watanabe S, Takada A et al. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 2001; 75: 1576-80.
7. Takada A. Filovirus tropism: cellular molecules for viral entry. Front Microbiol 2012; 3: 34.
8. Volchkov VE, Feldmann H, Volchkova VA et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998; 95: 5762-7.
9. Jeffers SA, Sanders DA, Sanchez A. Covalent modifications of the Ebola virus glycoprotein. J Virol 2002; 76: 12463-72.
10. Chan SY, Empig CJ,Welte FJ et al. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 2001; 106: 117-26.
11. Shimojima M, Takada A, Ebihara H et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 2006; 80: 10109-16.
12. Kondratowicz AS, Lennemann NJ, Sinn PL et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci USA 2011; 108: 8426-31.
13. Simmons G, Rennekamp AJ, Chai N et al. Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. J Virol 2003; 77: 13433-8.
14. Sinn PL, Hickey MA, Staber PD et al. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol 2003; 77: 5902-10.
15. Becker S, Spiess M, Klenk HD. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol 1995; 76: 393-9.
16. Alvarez CP, Lasala F, Carrillo J et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002; 76: 6841-4.
17. Simmons G, Reeves JD, Grogan CC et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003; 305: 115-23.
18. Takada A, Fujioka K, Tsuiji M et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 2004; 78: 2943-7.
19. Gramberg T, Hofmann H, Moller P et al. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 2005; 340: 224-36.
20. Mulherkar N, Raaben M, de la Torre JC et al. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology 2011; 419: 72-83.
21. Nanbo A, Imai M, Watanabe S et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathogens 2010; 6: e1001121.
22. Chandran K, Sullivan NJ, Felbor U et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308: 1643-5.
23. Carette JE, Raaben M, Wong AC et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477: 340-3.
24. Cote M, Misasi J, Ren T et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011; 477: 344-8.
25. Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 2006; 124: 119-31.
26. Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr Opinion Virol 2012; 2: 14-9.
27. Saeed MF, Kolokoltsov AA, Freiberg AN et al. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS pathogens 2008; 4: e1000141.
28. Goldschlager N, Epstein AE, Naccarelli G et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Int Med 2000; 160: 1741-8.
29. Kirsch T, Woywodt A, Beese M et al. Engulfment of apoptotic cells by microvascular endothelial cells induces proinflammatory responses. Blood 2007; 109: 2854-62.
30. Vondran FW, Katenz E, Schwartlander R et al. Isolation of primary human hepatocytes after partial hepatectomy: criteria for identification of the most promising liver specimen. Artificial Organs 2008; 32: 205-13
31. Gierer S, Bertram S, Kaup F et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87: 5502-11.
32. Flint M, von Hahn T, Zhang J et al. Diverse CD81 proteins support hepatitis C virus infection. J Virol 2006; 80: 11331-42.
33. Mittler E, Kolesnikova L, Strecker T et al. Role of the transmembrane domain of Marburg virus surface protein GP in assembly of the viral envelope. J Virol 2007; 81: 3942-8.
34. Ciesek S, Westhaus S, Wicht M et al. Impact of occludin intra- and inter-species variation on its co-receptor function for authentic hepatitis C virus particles. J Virol 2011; 85: 7613-21.
35. Hierholzer JC, Killington RA. Virus isolation and quantitation. London: Academic Press, 1996.
36. Ciesek S, Steinmann E, Wedemeyer H et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009; 50: 1638-45.
37. Ciesek S, von Hahn T, Colpitts CC et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 2011; 54: 1947-55.
38. Lupberger J, Zeisel MB, Xiao F et al. EGFR and EphA2 are host factors for hepatitis Cvirus entry and possible targets for antiviral therapy. Nature Med 2011; 17: 589-95.
39. Randhawa PS, Farasati NA, Huang Y et al. Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication. Am J Clin Pathol 2010; 134: 916-20.
40. Gazina EV, Harrison DN, Jefferies M et al. Ion transport blockers inhibit human rhinovirus 2 release. Antiviral Research 2005; 67: 98-106.
41. Nemerow GR, Cooper NR. Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci USA 1984; 81: 4955-9.
42. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovascular Research 1997; 35: 13-29.
43. van Paassen J, Bauer MP, Arbous MS et al. Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infect Dis 2012; 12: 635-42.
44. Maruyama T, Rodriguez LL, Jahrling PB et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999; 73: 6024-30.
45. Geisbert TW, Lee AC, Robbins M et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375: 1896-905.
46. Geisbert TW, Daddario-DiCaprio KM, Williams KJ et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82: 5664-8.
47. Shoemaker CJ, Schornberg KL, Delos SE et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PloS One 2013; 8: e56265.
48. Johansen LM, Brannan JM, Delos SE et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Trans Med 2013; 5: 190ra79.
49. Piccoli E, Nadai M, Caretta CM et al. Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype. Biochem Pharmacol 2011; 82: 1234-49.
50. Stadler K, Ha HR, Ciminale V et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. American J Resp Cell Mol Biol 2008; 39: 142-9.
51. Rojek JM, Sanchez AB, Nguyen NT et al. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol 2008; 82: 7677-87.
52. Rojek JM, Kunz S. Cell entry by human pathogenic arenaviruses. Cellular Microbiol 2008; 10: 828-35.
53. Kornhuber J, Tripal P, Reichel M et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008; 51: 219-37.
54. Hasegawa J, Fujita T, Hayashi Y et al. pKa determination of verapamil by liquid-liquid partition. J Pharmaceutical Sci 1984; 73: 442-5.
55. Jin M, Park J, Lee S et al. Hantaan virus enters cells by clathrindependent receptor-mediated endocytosis. Virology 2002; 294: 60-9.
56. Dorkkam N, Wongdee K, Suntornsaratoon P et al. Prolactin stimulates the L-type calcium channel-mediated transepithelial calcium transport in the duodenum of male rats. Biochem Biophys Res Commun 2013; 430: 711-6.
57. Moccia F, Berra-Romani R, Tanzi F. Update on vascular endothelial Ca(2+) signalling: a tale of ion channels, pumps and transporters. World J Biol Chem 2012; 3: 127-58.
58. Clapham DE. Calcium signaling. Cell 2007; 131: 1047-58.
59. Lavanya M, Cuevas CD, Thomas M et al. siRNA screen for genes that affect Junin virus entry uncovers voltage-gated calcium channels as a therapeutic target. Sci Trans Med 2013; 5: 204ra131.